Endometrial Cancer: Global Market Forecasts to 2023 - ResearchAndMarkets.com

DUBLIN--()--The "Global Endometrial Cancer Market - Segmented By Type of Cancer, Therapy, Diagnosis Method, and Geography - Growth, Trends, and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.

The Endometrial Cancer Market is expected to witness a lucrative growth during the forecast period.

According to the American Cancer Society, in 2017, about 61,380 new cases of uterus body cancer have been diagnosed, and about 10,920 women died due to the uterine cancer. This market is likely to witness a significant growth, leading to an increase in the opportunity for the drug manufacturers.

The rising healthcare expenditure among the urban population and the initiatives taken by various governments for improving their healthcare infrastructure, is fueling the global endometrial cancer market. The presence of the equitable, responsive, and efficient health systems present across the countries in North America, Europe, and the Asia-Pacific has contributed to the maximum share of the GDP being utilized as healthcare expenditure.

The US healthcare expenditure has grown by 5.8% in 2015, amounting to USD 3.03 trillion or USD 9,451 per person. Norway and Switzerland are the next big spenders on health per capita. Some of the other countries with maximum healthcare spending includes Germany, Canada, and the Netherlands, among others. The above given statistics shows that the overall expenditure for healthcare is on a rise in many of the countries, thus driving the market for endometrial cancer.

The other factors driving the market for the endometrial cancer include rise in awareness of uterine diseases and their available therapies, innovation in drug development, and growth of diagnostic tests.

North America holds the major market, owing to the large number of research and development activities, along with high healthcare expenditure. In the United States, endometrial cancer is the most common type cancer of the female reproductive system and is the fourth most common cancer among women. Europe is expected to hold the second largest share in the global market, due to the growing product availability in the regions.

Key Developments in the Market

  • January 2018: Eisai and Merck receive a breakthrough therapy designation from FDA for LENVIMA (lenvatinib mesylate) and KEYTRUDA (pembrolizumab) as a combination therapy for the advanced and/or metastatic renal cell carcinoma.

Key Topics Covered

1. Introduction

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)

7. Market Segmentation

8. Competitive Landscape

9. Key Players

  • Ariad Pharmaceuticals
  • Abbott Laboratories
  • Becton Dickinson & Co.
  • Glaxosmithkline
  • Merck
  • Novartis AG
  • Sanofi
  • Siemens Healthcare
  • Roche

10. Future of the Market

For more information about this report visit https://www.researchandmarkets.com/research/qfm7tc/endometrial?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Uterine Cancer Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Uterine Cancer Drugs